Keryx Biopharmaceuticals (KERX) jumps 7.4% after announcing an independent agency has...

|By:, SA News Editor

Keryx Biopharmaceuticals (KERX) jumps 7.4% after announcing an independent agency has recommended the company's Phase 3 study of its Perifosine drug for treating Colorectal Cancer continue to completion. Aeterna Zentaris (AEZS), which has licensed Perifosine to Keryx, is up 2.5%. (yesterday)